Raising awareness on Lipoprotein(a) as a key cardiovascular risk factor

Cardiovascular diseases (CVDs) continue to be the top cause of death globally, with significant economic repercussions. Lipoprotein(a), or Lp(a), is a genetic risk factor impacting around 20% of people, significantly heightening the risk of atherosclerotic cardiovascular disease (ASCVD).

The importance of Lp(a)

Lp(a) is a cholesterol-protein particle closely linked to ASCVD risk. Unlike other risk factors, Lp(a) levels are primarily genetic and less affected by lifestyle changes. Elevated Lp(a) boosts ASCVD risk by 2.7 times and is six times more atherogenic than LDL cholesterol.

Action steps

Key priorities include:

• Recognize Lp(a) as independent, genetic risk factor.

• Use Lp(a) as a new asset for driving efficiency in CV prevention.

• Implement accessible testing for Lp(a).

• Leverage the potential of e-health in managing Lp(a).

• Build a broad, evidence-based educational campaign to promote health equality.

Integrating Lp(a) testing in Belgium

Routine Lp(a) testing can prevent heart attacks and strokes and is cost-effective. Working with policymakers to include Lp(a) testing in the national cardiovascular health plan and reimbursement schemes is crucial. 

Enhancing data and communication

Centralised data collection and consistent lab reporting will support better diagnosis and patient understanding. Reporting should include clear interpretation aligned with European guidelines.

Conclusion

Incorporating Lp(a) testing into cardiovascular prevention is essential for improving public health in Belgium. Coordinated efforts in education, data, and resource allocation can reduce premature deaths and healthcare costs.